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Abstract
Background: Phospholipase A2 liberates free fatty acids and lysophospholipids upon hydrolysis of
phospholipids and these products are often associated with detrimental effects such as
inflammation and cerebral ischemia. The neuroprotective effect of neutral phospholipase from
snake venom has been investigated.
Results: A neutral anticoagulant secretory phospholipase A2 (nPLA) from the venom of Naja
sputatrix (Malayan spitting cobra) has been found to reduce infarct volume in rats subjected to focal
transient cerebral ischemia and to alleviate the neuronal damage in organotypic hippocampal slices
subjected to oxygen-glucose deprivation (OGD). Real-time PCR based gene expression analysis
showed that anti-apoptotic and pro-survival genes have been up-regulated in both in vivo and in vitro
models. Staurosporine or OGD mediated apoptotic cell death in astrocytoma cells has also been
found to be reduced by nPLA with a corresponding reduction in caspase 3 activity.
Conclusion: We have found that a secretory phospholipase (nPLA) purified from snake venom
could reduce infarct volume in rodent stroke model. nPLA, has also been found to reduce neuronal
cell death, apoptosis and promote cell survival in vitro ischemic conditions. In all conditions, the
protective effects could be seen at sub-lethal concentrations of the protein.
Background
Phospholipase A2 (PLA2; EC 3.1.1.4) forms a diverse class
of enzymes with regard to structure, function, localization
and regulation. The enzyme catalyzes the hydrolysis of the
sn-2 fatty-acyl bond of phospholipids to liberate free fatty
acids and lysophospholipids [1]. Major groups of phos-
pholipase A2 that have been actively studied in mamma-
lian systems include a) cytosolic Ca2+-dependent (cPLA2)
or Ca2+-independent (iPLA2) [2,3] and b) Ca2+-dependent
secretory (sPLA2) phospholipase A2. Both the cPLA2 and
iPLA2 are high molecular weight (85-110 kDa) intracellu-
lar enzymes [4] and they have been widely associated with
multifaceted network of signaling pathways. However,
PLA2 that acts on membrane phospholipids has been
implicated in cell death and differentiation as well as
intracellular membrane trafficking [5].
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In mammalian cells, PLA2 activity has been found to
increase in response to numerous stimuli such as osmotic
challenge, oxidative stress, ischemic conditions and expo-
sure to allergens. The synthesis of different cell specific
sub-types and activation of mammalian PLA2 are associ-
ated with cell injury and various pathophysiological con-
ditions [6]. In the central nervous system (CNS), PLA2 is
known to participate in many (patho)physiological activ-
ities [5,7] and has been found to increase significantly fol-
lowing spinal cord injury [6]. The role of PLA2 has also
been documented in schizophrenia, brain trauma and
Alzheimer's disease [8,9] besides global and focal
ischemia in animal models [10]. Hippocampal slices sub-
jected to oxygen and glucose deprivation (OGD) have
been found to show an increase in PLA2 activity and a con-
comitant death of neuronal cells. Inhibition of cPLA2 has
been found to result in an enhanced survival of the hip-
pocampal neurons [11]. Evidently, cPLA2 knock-out mice
subjected to focal cerebral ischemia showed significant
reduction in infarct volume and the extent of neurological
impairment [12]. Furthermore, Strokin et al [13] demon-
strated that inhibition of iPLA2 during OGD could render
neuroprotection to the hippocampal slice cultures. Fur-
thermore, simultaneous inhibition of cPLA2 and sPLA2
activities have also been shown to improve survival of
glial cells subjected to ischemic injury [14].
The snake venom PLA2 belongs to the Ca2+-dependant
secretory PLA2. Venom phospholipases A2  possess an
enzymic activity and a wide variety of (patho)pharmaco-
logical activities such as antiplatelet, anticoagulant,
hemolytic, neurotoxic (presynaptic), myotoxic, edema-
inducing, hemorrhagic, cytolytic, cardiotoxic as well as an
ability to bind antagonistically to muscarinic acetylcho-
line receptor (mAChR) [15-17]. The snake venom phos-
pholipases are divided into two main groups, group I and
group II, based on their primary structures [1]. The group
I PLA2 is found in abundance in the venom of cobras,
kraits and sea snakes, while group II PLA2 is common in
vipers and pit vipers. The cobra venom PLA2 belongs to
group IA that is similar to the pancreatic type group IB
protein but without the signature pancreatic loop struc-
ture. Venom of Naja sputatrtix, a Malayan spitting cobra,
comprises of three isoforms (2 neutral and 1 acidic) of
group 1A PLA2. One of the neutral forms, nPLA-1 (nPLA)
is a highly potent anticoagulant protein that exhibits rela-
tively high enzymic activity [18-20]. This protein has also
been shown to possess an ability to bind to all muscarinic
receptor subtypes (m1-5) with a higher affinity to the m5
subtype [16].
In this report, in contrast to the reported detrimental
effects of mammalian phospholipase A2 to the central
nervous system, we demonstrate that neutral PLA2 (nPLA)
from Naja sputatrix could reduce neuronal cell death and
afford neuroprotection to rat brain subjected to transient
focal ischemia. Furthermore, OGD induced tissue injury
has also been found to be reduced in the presence of
nPLA. Real-time quantitative gene expression analysis
showed that the pro-survival and anti-apoptotic genes
have been upregulated. Both caspase 3 (in vitro, cell cul-
ture) and TUNEL (in vivo, brain slices) assays showed that
apoptotic cell death can be reduced upon treatment with
nPLA.
Methods
Purification of nPLA
Phospholipase A2 (nPLA) was purified from Naja sputatrix
crude venom (Sigma Chemicals Co., USA) using Sepha-
dex G-100 gel filtration followed by reverse phase high
performance liquid chromatography (RP-HPLC). The
protein fractions were characterized as described by
Armugam et al [18] and quantitated using the Bradford
assay (Bio-Rad Laboratories, CA).
Transient focal cerebral ischemia
Male Sprague-Dawley rats (200-300 g) were obtained
from the Laboratory Animal Centre (National University
of Singapore, Singapore) and maintained on an ad libitum
intake of standard laboratory chow and drinking water.
All animals were handled according to the guidelines
given by the Council for International Organization of
Medical Sciences (CIOMS) on animal experimentation
(WHO, Geneva, Switzerland) and the National University
of Singapore (IACUC/NUS) guidelines for handling labo-
ratory animals. Animals were anaesthesized and left mid-
dle cerebral artery occlusion (MCAo) was performed as
described by Longa et al [21]. The occlusion was con-
firmed with the real-time measurement of cerebral blood
flow (CBF) in the territory of the middle cerebral artery
(MCA) using the Laser-Doppler flowmetry (OxyFlo,
Oxford Optronix) and the signals were digitized using a 4-
channel Powerlab 4SP (ML760) and recordings were dis-
played with Chart 5 software (ADInstruments Pty Ltd,
Australia). Reperfusion was initiated by suture withdrawal
after 60 min. nPLA (0.075-0.25 μg/g body weight) was
injected intravenously via the femoral vein at various
times of post-occlusion.
Recombinant tissue plasminogen activator (tPA; Boe-
hringer Ingelheim, Germany) was infused intravenously
at a concentration of 10 μg/g body weight over a period of
60 min, starting 30 min post-occlusion. MK801 (Sigma-
Aldrich Co., USA) was administered intraperitoneally in 3
doses: 2.5 μg/g body 30 min prior to MCAo followed by
1.25 μg/g body weight at 6 and 14 hr post-occlusion. Cor-
responding controls were treated with sterile saline and all
animals were sacrificed after a total of 24 hr reperfusion
period.BMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
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Whole brains were rapidly removed and snap-frozen in
liquid nitrogen. Frozen brains were stored at -80°C until
use. Consequently, there were 5 treatment groups: [1]
Sham-operated (sham-op, n = 7); [2] Transient MCAo
(MCAo) for 60 min and administered with 100 μl saline
(MCAo, n = 10); [3] Transient MCAo for 60 min and
administered with nPLA intravenously (MCAo+nPLA, n =
20); [4] Transient MCAo for 60 min and administered
with tPA intravenously (n = 6); [5] Transient MCAo for
60 min and administered with MK801 intraperitoneally
(n = 6).
Quantitation of the ischemic infarct volume
Whole rat brains were sliced coronally into 1 mm slices
and incubated in 2, 3, 5-triphenyltetrazolium chloride
(TTC; Sigma, St Louis, MO, USA) and fixed in 10% buff-
ered formalin. Stained brain slices were scanned and the
image was analysed using Scion Image analysis software
for measurement of the infarct volume. The infarct size
was determined according to Engelhorn et al [22]. His-
topathological changes in the brains were evaluated from
paraffin embedded brain slices. Cell morphology assess-
ment was carried out using the haematoxylin and eosin
staining. The degree of apoptotic neuronal cell death was
assessed by TUNEL staining using the ApopTag® Peroxi-
dase In situ Apoptosis Detection kit (Chemicon Interna-
tional, USA) according to manufacturer's protocol.
RNA isolation and real-time quantitative PCR
Total RNA was isolated from brain tissues (frozen or
fresh) by a single-step method using TRIzol® Reagent (Inv-
itrogen, USA). The RNA samples were treated with RNase-
free DNase at 37°C for 20 min and stored at -80°C until
further use. Reverse transcription of total RNA and real-
time PCR studies using SYBR-Green chemistry (Applied
Biosystems, USA) were carried out according to Cher et al
[23]. A dissociation protocol was carried out at the end of
each experiment that was performed in triplicates and
repeated at least 3 times for each case.
Organotypic hippocampal slice culture
Organotypic hippocampal slice cultures were prepared as
described previously [24] with slight modifications.
Briefly, hippocampii from 6 to 8 days old Sprague Dawley
rat pups were dissected and sliced to 350 μm thickness
and placed in ice-cold growth medium (50% MEM, 25%
HBSS, 25% heat inactivated horse serum, 5 mg/mL glu-
cose, 1 mM glutamine, 1.5% fungizone). The sliced tis-
sues were placed onto semiporous membranes (culture
plate inserts; Millicell, Milipore Co, Bedford, MA) and
grown for 10 to 14 days at 37°C with 5% CO2 enriched
atmosphere before subjecting to oxygen and glucose dep-
rivation (OGD) studies. Propidium iodide (PI; 5 μg/ml)
was included in the culture media during the experiments
to trace the damage on the tissues.
Oxygen-glucose deprivation (OGD)-mediated ischemic 
injury
Organotypic hippocampal cultures were grown in basal
medium (75% MEM, 25% HBSS, 1 mM glutamine, and
1.0% penicillin-streptomycin) and transferred to six-well
plates containing glucose-free medium (75% glucose-free
MEM, 25% HBSS, 1 mM glutamine and 1.0% penicillin-
streptomycin) saturated with 95% N2, 5%CO2 and placed
into an anaerobic chamber at 37°C and 100% humidity
for 90 mins. nPLA (0.0375 μM, 0.075 μM and 0.15 μM),
was dissolved in distilled water and added to the medium
immediately before exposure to OGD. After 90 mins, the
cultures (culture plate semiporous inserts) were then
transferred to a fresh 6 well plate containing pre-warmed
serum free medium with 5 μg/mL propidium iodide [24]
and incubated in the CO2 chamber for 24 hours. The hip-
pocampal slices were viewed under confocal microscope
and analysis of damaged CA1 hippocampal neurons fol-
lowing OGD was carried out using ImagePro Plus Soft-
ware (Media Cybernetics, Silver Spring, MD, U.S.A.).
Hippocampal culture in serum free media was used as
controls in all experiments.
Astrocytoma (CRL1718™) cell culture
The human astrocytoma cells (CRL-1718™, ATCC) were
cultured in RPMI 1640 media (Hyclone Laboratories,
USA) supplemented with 10% fetal bovine serum (FBS),
1% L-glutamine and 1% Penicillin-streptomycin (GIBCO-
BRI, Gaithersburg MD, USA) and maintained in a 37°C
incubator with 5% CO2. Cells were checked regularly
under the light microscope and were divided into appro-
priate culture plates when they reached 70-80% conflu-
ence. Cells were subcultured at a density of 1.0 × 105 cells
(24-well plates) or 1.25 × 104 cells (96-well plates) as
required and subjected to either staurosporine or OGD
treatment(s).
Detection of TNF-α, cytotoxicity assay and caspase assay
Detection of TNF-α (inflammation marker) in the blood
serum of rats subjected to MCAo (treated with either nPLA
or LPS) was carried out using the Chemikine™ Rat TNFα
Sandwich ELISA kit (Chemicon International, USA)
according to manufacturer's protocol. Blood samples
from Sprague Dawley rats (n = 6) with and without MCAo
were administered intravenously with saline (100 μl) or
nPLA (0.15 μg/g body weight) or intraperitoneally with
bacterial lipopolysaccharide (LPS; 2 μg/g body weight).
LPS was used as a positive control to induce inflammation
and for the release of TNF-α.
In organotypic hippocampal slice culture studies, cell
death measurement was carried out using the lactate
dehydrogenase (LDH) assay (Roche Life Science, Ger-
many). Briefly, the LDH activity in the culture media was
measured spectrophotometrically at 490 nm using aBMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
Page 4 of 13
(page number not for citation purposes)
multi-plate scanning spectrophotometer (Model 680
Microplate Reader, Bio-Rad Laboratories, CA) at an end
point of 30 min. Caspase-3-like protease activity was
measured by fluorometric assay (Axxora Life Sciences Inc.,
USA). DEVD-AFC was used as substrate for caspase activ-
ity of the cell lysate and the cleaved AFC (7-amino-4-trif-
luoro-methyl coumarin) was measured in a
spectrofluorometer at 400/505 nm (excitation/emission).
Microarray analysis
Total RNA isolated from sham, MCAo and MCAo+nPLA
brains was pooled to minimize inter-individual variation
and hybridized to each array of the RAE-230A or U34A
GeneChip™ according to protocols described in the Gene-
Chip™ expression analysis package (Affymetrix, CA). Each
chip represented ~15,900 genes and ESTs and data for
each treatment were scaled to an average intensity of 800.
Probe sets designated 'absent' in all treatments by the
analysis software were discarded and only genes whose
expressions were changed by 0.6-fold or greater in each
pairwise comparison (between sham-op and MCAo or
between MCAo and MCAo+nPLA) were deemed signifi-
cant. Differentially expressed genes (p < 0.025) were clas-
sified according to their biological functions as described
in the NetAffx Analysis Center http://www.affyme
trix.com/analysis/index.affx and PubMed http://
www.ncbi.nlm.nih.gov databases. The data discussed in
this publication have been deposited in NCBI's Gene
Expression Omnibus [25] and are accessible through GEO
Series accession number GSE17929, http://
www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE17929.
Statistical analysis
All statistical analysis was carried out using single-factor
ANOVA followed by (a) Dunnett multiple comparison
tests for MCAo brain slice analysis and (b) for all other in
vitro experiments, pairwise comparisons were carried out
using unpaired Student's t-test.
Results
nPLA reduces infarct volume in MCAo rat model
The nPLA native protein, was purified from Naja sputatrix
according to the methods described by Armugam et al
[18]. The purity and identity of this protein was confirmed
by mass spectrometry and N-terminal sequencing before
using in this study. Naja sputatrix venom contains three (2
neutral and 1 acidic) isoforms of PLA2. Their molecular
mass is approximately 14 kDa and all of them have anti-
coagulant and phospholipase activity [20]. Among them,
the nPLA is a most potent anticoagulant, with an enzymic
activity and also competes with atropine for the mus-
carinic receptor [16].
The anti-ischemic and neuroprotective property of the
nPLA was initially observed in vivo, in rat model subjected
to transient middle cerebral artery occlusion (MCAo).
nPLA was administered intravenously, at doses of 0.075
μg/g, 0.15 μg/g, 0.25 μg/g, body weight (0.15 μg/g = 0.25
LD50 = 1 μg/ml = 0.075 μM) immediately 0 min, 5 min
and 15 min after MCAo. However, the highest neuropro-
tective effect (measured initially as reduction in the infarct
volume) has only been observed at the 0.15 μg/g rats and
therefore all experiments were conducted at this concen-
tration of nPLA2 (Figure 1a &1b). The administration of
nPLA immediately upon occlusion (0 min) resulted in a
significant reduction (~70% reduction) in infarct size, as
observed by triphenyltetrazolium chloride (TTC) staining
of serial brain sections (Figure 1a). Ischemic damage was
markedly attenuated in the striatum and cortex of the
brain, with more pronounced protection in striatal tissue.
Administration of nPLA at 5 min post-MCAo also reduced
the infarct size but to lesser extent (~15% reduction; Fig-
ure 1b). No protection was observed at 15 min or later.
The abilities of tPA and a non-competitive antagonist of
the NMDA receptor, Dizocilpine (MK801) to reduce inf-
arct volume was used as controls and were compared to
that of nPLA. Intravenous infusion of 10 μg/g body weight
tPA did not significantly reduce infarct volume after tran-
sient ischemia (see Additional file 1a&1b). The inability
of tPA to prevent neuronal death is perhaps not surprising
since its efficacy has mainly been demonstrated in
embolic stroke models [26] or after mild transient focal
ischemia [27]. On the other hand, the intra-peritonial
administration of MK801 in three doses (total of 5.0 μg/
g), at 2.5 μg/g body weight about 30 min prior to MCAo
and followed by 1.25 μg/g body weight at 6- and 14 hr
post-occlusion [28] significantly reduced infarct volume
to 61.1% ± 8.6% as compared to the vehicle control (see
Additional file 1a&1b). The extent of neuroprotection
conferred by MK801 is however lower than that observed
for nPLA (33.2% ± 5.1%) administered immediately post-
occlusion. Nevertheless, the MK801 conferred neuropro-
tection was significantly higher than that conferred by
nPLA given after 5 min of MCAo (78.3% ± 10.8%; Figure
1b & see Additional file 1b). It should be noted that
MK801 was administered at 3 time points (2.5 μg/g and
twice at 1.5 μg/g) while the nPLA was administered only
once at 0.15 μg/g. Thus the efficacy of nPLA mediated pro-
tection can be considered to be more pronounced than
that of the positive control, MK801. TNF-α has been dem-
onstrated to be elevated upon MCAo and this increase in
TNF-α activity results in increase of the endogenous sPLA2
expression/activity that is implicated in neuronal damage
in ischemic models [29]. Intraperitoneal administration
of bacterial LPS (positive control for TNF-α induction)
dramatically increased plasma TNF-α levels (232 ± 25.1
pg/ml) as compared to the saline-treated control (2.6 ±
0.05 pg/ml). In contrast, nPLA2 failed to induce signifi-
cant TNF-α release or expression in both normal and
ischemic rats (4.1 ± 0.03 pg/ml and 1.0 ± 0.01 pg/ml
respectively; see Additional file 1c). Thus, the 0.25 LD50BMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
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nPLA (0.15 μg/g body weight in rats) does not induce
inflammation or cytotoxicity as previously observed by
Tan and Armugam [20].
Reduction in apoptotic cell death upon nPLA treatment
The paraffin-embedded rat brain (MCAo, MCAo+nPLA)
sections were stained with haematoxylin and eosin and
cellular morphology was evaluated using light micros-
copy. Extensive tissue damage and edema were observed
in the striatum and cortex of MCAo brain slices (Figure
2a). Neurons appeared shrunken and nuclei were dysmor-
phic and pyknotic, consistent with apoptotic cell death
[30]. TUNEL assay was carried out to assess the extent of
apoptosis in ischemic brains (Figure 2b). Control cells
appeared green whereas almost all the neurons in the
striatum and cortex of ischemic brains (MCAo) exhibited
apoptosis and their nuclei were stained brown. The degree
of apoptosis was greatly reduced by the administration of
nPLA immediately post-occlusion as evidenced by the
substantial reduction in number of apoptotic cells. Fur-
thermore, real-time PCR analysis on selected genes encod-
ing apoptosis related proteins (Bcl-2, Bcl-XL and Bax) and
the survival pathway mediating proteins (NF-κB and IκB)
as well as the signalling pathway proteins (PI3K, Erk1),
and ion and water channel proteins (Kir4.1, Na+K+-ATPase,
Aqp4 and Aqp9), showed (Figure 2c) that the nPLA treat-
ment reduces the effects of MCAo-mediated neuronal/cell
damage via promoting cell survival/protective mecha-
nisms. Similarly, we have also observed that stau-
rosporine (STS)-mediated cell death in human
astrocytoma cells (CRL1718™) could be alleviated by 0.01
μM nPLA (Figure 3a). The reduction in cell death has also
been found to be accompanied by a decrease in caspase-3
activity (Figure 3b). Furthermore, inclusion of 0.038 μM
nPLA in the basal media during OGD, protected the astro-
cytoma cells from cell death. Improved cell viability has
always been accompanied by a significant reduction in
caspase-3 activity (Figure 3c).
nPLA-mediated neuroprotection in in vitro studies
nPLA-mediated neuroprotection was also observed in the
organotypic hippocampal culture subjected to OGD (Fig-
ure 4a). Almost complete (97 ± 0.81%) protection was
seen at 0.15 μM nPLA, which is similar to the protection
induced by positive control, MK801 (Figure 4b). LDH
assay showed that nPLA could reduce the cytotoxicity
induced by OGD. The Bcl-2 (1.2 ± .018 and 2.27 ± 0.02
fold) and Bcl-XL (1.17 ± 0.025 and 1.69 ± 0.03 fold) genes
were upregulated whereas Bax (-2.27 ± 0.016 and -1.97 ±
0.129 fold) was found to be downregulated in the organ-
otypic hippocampal slice culture in OGD conditions at
both 0.075 μM and 0.15 μM nPLA respectively (Figure
4c). Similarly, concurrent (during glutamate incubation)
and post-treatment with nPLA showed reduced neuronal
injury in a dose-dependent manner in hippocampal slice
culture (both the CA1 and CA3 regions) subjected to
glutamate induced excitotoxicity (data not shown).
Global gene expression analysis
Global gene expression analysis by oligonucleotide
microarray in MCAo and MCAo+nPLA showed a total of
Histological analysis of brain sections Figure 1
Histological analysis of brain sections. (a) TTC stained coronal brain sections (2 mm thick) of rats treated with 0.15 μg/g 
body weight nPLA intravenously at 0 min, 5 min and 15 min post-occlusion (n = 6). Surviving cells stained red whilst dead cells 
remained white. (b) Infarct volumes are expressed as a percentage of the vehicle control ± SEM. *, p < 0.05; **, p < 0.01 using 
single-factor ANOVA followed by Dunnett multiple comparison test.
a bBMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
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1455 genes (filtering criteria; 0.6<SLR<-0.6 and detection
p value < 0.025).
Among these, the endogenous phospholipases (PLA2 and
PLC) have been found to be upregulated upon treatment
of the the MCAo rats with nPLA (Figure 5a&5b). The
expression of cPLA2 (PLA2-4A), reported to contribute to
the pathophysiological conditions and neurological defi-
cits during stroke, has also been found to be significantly
higher in the nPLA treated rats. On the other hand, the
iPLA2 (a calcium-independent Group 6 cytosolic PLA2),
has been found to be downregulated in both the control
and nPLA treated MCAo rats. It is noteworthy that the
PLCs (with exception to PLCδ4, PLCγ1) that are involved
in Ca2+ dependent signal transduction activities remained
highly upregulated in the nPLA treated animals. However,
following a prolonged (48 hr) reperfusion the expression
of all the endogenous phospholipases except PLA2-1B,
PLA2-2A and PLA2-2C reached a basal level comparable to
that of the control. nPLA treatment showed an upregula-
tion of PLA2-1B, -2A and -2C and a downregulation of
endogenous iPLA2(Figure 5c).
The microarray dataset when clustered by k-means cluster-
ing using the Genesis software package [31] gave 15 clus-
ters of which clusters 1 and 6 (see Additional file 2)
represented the genes that were fully restored to sham lev-
els following nPLA treatment (see Additional file 3 &4).
Anti-apoptotic effect of nPLA (a) Histological and TUNEL analysis of brain sections Figure 2
Anti-apoptotic effect of nPLA (a) Histological and TUNEL analysis of brain sections. High power (×120) photomi-
crographs of haematoxylin and eosin-stained (b) TUNEL-stained striatal and cortical tissue. Nuclei are indicated by 
arrows. Rats subjected to transient MCAo were injected intravenously with either vehicle or 0.15 μg/g body weight nPLA. 
Sham-operated animals underwent the entire surgical procedure other than suture insertion. (c) Quantitative gene 
expression (real-time PCR) analysis. Gene expression analysis on selected genes for sham operated (Sham), MCAo and 
MCAo+nPLA brain samples. All measurements were performed in triplicate. Values are expressed as fold change ± SEM, * p < 
0.05; ** p < 0.01 by unpaired Student's t-test.
a b
cBMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
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(a) Effect of nPLA (0.01 μM) on dose-dependent STS-induced cell death in astrocytoma cells (CRL1718™) Figure 3
(a) Effect of nPLA (0.01 μM) on dose-dependent STS-induced cell death in astrocytoma cells (CRL1718™). Cell 
viability assay was carried out following 16 hrs exposure to various concentrations of STS or STS + 0.01 μM nPLA. Asterisks 
denote difference from its each individual STS concentration treatment. Values are expressed as percentage of viability (to the 
respective treatment without nPLA) ± SEM, * p < 0.05 by unpaired Student's t-test (n = 9). (b) Effect of nPLA on STS-
induced cell death by caspase-3 activity assay. Control: no reagents, STS: 1.5 μM STS, STS + nPLA: 1.5 μM STS+0.01 μM 
nPLA. Data shown are mean ± SEM (n = 18). (c) Effect of nPLA on CRL1718™ astrocytoma cells subjected to OGD. 
Cells were subjected to 2 hr OGD and nPLA (0.038 μM or 0.01 μM) was added in the culture during the ischemic period. Cell 
viability assay was carried out following a 24 hr of reperfusion. Caspase-3 assay was carried out on the respective cell lysates. 
Data shown are mean ± SEM (n = 3, conducted in triplicates, p < 0.05, two tail Student's t test).
a
b
cBMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
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The genes in cluster 1 (downregulated) and cluster 6
(upregulated) during MCAo revert to normal (Sham) level
of expression upon nPLA treatment. The gene ontology
classes can also be seen to be quite similar in both clusters
1 & 6. The major sites (cellular component) of action of
nPLA appear to be the membrane and nucleus, implicat-
ing involvement of receptors and signaling pathways. This
is further observed in pathway analysis using Gene Ontol-
ogy (GO) and GENMAPP program [32] where most of the
pathways involved are signalling pathways. Cluster 6 con-
tains genes that are localized in the ribosome as well.
Nucleotide binding (ATP binding) is the most common
functional GO class found for both clusters. Interestingly
there are several ion binding related GO classes such as
calcium and zinc ion binding that are common to both
clusters, implicating the involvement of nPLA in the regu-
lation of ionic levels of the cells. G-protein coupled recep-
tor (GPCR) protein signalling pathway and intracellular
protein transport are among the several common proc-
esses that were observed in both the clusters 1 & 6.
The pathways involved in apoptosis (Epithelial growth
factor receptor (EGFR) 1, TNF-alpha-NF-kB and MAPK
signalling pathways) and inflammation (Interleukin and
T-cell receptor and B-cell receptor signalling pathways),
were observed to be highly affected by nPLA treatment in
MCAo rats. NFκB1 which is upregulated in nPLA treat-
ment directly inhibits apoptosis (see Additional file 5).
EGFR1 pathway regulates apoptosis and many genes of
Organotypic hippocampal culture subjected to OGD Figure 4
Organotypic hippocampal culture subjected to OGD. (a) Slices subjected to oxygen-glucose deprived (OGD) condi-
tion in the presence of nPLA (0.037 μM-0.15 μM) and propidium iodide (5 μg/ml). Confocal microscopy images show that 
brighter areas correspond to a high propidium iodide [24] uptake level indicating a higher density of dead or damaged cells. (b) 
Percentage of cell survival, calculated based on PI intensity on each CA1 and CA3 regions. Each point represents the mean 
± SEM (n = 8). #; p < 0.05 and *; p < 0.01. (c) Quantitation of gene expression using real-time PCR. Statistical analysis 
was performed using one-way analyses of variance (ANOVA; *; p ≤ 0.005.) and a t-test to determine significance between 
groups for LDH assay (n = 6) and real-time PCR (n = 9).
a
b cBMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
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Microarray analysis on the endogenous phospholipases Figure 5
Microarray analysis on the endogenous phospholipases. (a) Hierachical clustering of all the phospholipases 
detected in our global gene expression studies. Signal log(2) ratio (vs normal control) of the average signal intensities (detection 
p value < 0.01) were used to construct the dendrogram and the genes and samples were clustered based on Euclidean distance 
and average linkage method (TIGR MultiExperiment Viewer; [52]). (b) expression of endogenous phospholipases at 24 hour 
reperfusion (c) expression of endogenous phospholipases at 48 hour reperfusion. Control, sham operated rat brain; MCAo, 
rats subjected to middle cerebral artery occlusion and reperfused for either 24 hr or 48 hr; PLA, MCAo rat administered with 
nPLA (0.15 μg/g rats) and allowed reperfusion for 24 hr or 48 hr.
a
b
cBMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
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this pathway can be seen in clusters 1 and 6 (see Addi-
tional file 6). Hspa1a also known as HSP70 that inhibits
apoptosis was found to be further upregulated upon nPLA
treatment than MCAo (see Additional file 7). NFkb1
which is upregulated only in nPLA treatment is known to
enhance cell survival. Thus, nPLA treatment appeared to
protect the cell by anti-apoptotic as well as cell survival
mechanisms.
Discussion
nPLA reduces infarct volume and protects neurons from 
cell death
In this report, we demonstrate that nPLA could reduce
apoptotic cell death and render neuroprotection against
cerebral ischemia. Intravenous administration of nPLA to
the MCAo rats at 0 min and 5 min post-occlusion reduced
infarct volumes to 33.2% and 78.3% respectively as com-
pared to the vehicle control. Saluja et al [33] observed sig-
nificant increase in cPLA2 activity and expression after 10
mins and 20 mins upon onset of global ischemia. Further-
more, in an in vitro study, cPLA2 activity was not detected
in the absence of calcium ion [34]. Thus, these reports
could explain our observation that administration of
nPLA at only 0 min (initiation of occlusion) and 5 mins
and not after 15 mins of occlusion, showed neuroprotec-
tion in our rat MCAo model. Significant reduction in
ischemic damage has also been observed in histological
analysis of the brain slices, where many cell nuclei exhib-
ited normal morphology in nPLA treated MCAo rat brain.
Neurons within the ischemic core die largely by means of
a necrotic mechanism as a result of the excitotoxicity cas-
cade triggered by energy depletion while damage within
the penumbra is mediated by mechanisms such as apop-
tosis. During cerebral ischemia, sub-lethal injury to neu-
rons favours the initiation of apoptosis in the penumbral
neurons [35]. The nPLA-mediated protection has been
found to target the area/region where cells are undergoing
apoptosis and consequently reducing cell death as
observed in the TUNEL assay. Daniel and DeCoster [36]
have demonstrated that TUNEL staining could be used as
apoptosis marker and is significant at later times (>4 hr
and <26 hr) of cell death. Hence, nPLA appears to possess
the ability to protect, possibly the penumbra region from
ischemic damage. Furthermore, nPLA-mediated 'protec-
tion' was also observed in human astrocytoma cells (CRL-
1718™) exposed to staurosporine (STS) where increased
cell viability and reduction in caspase 3 activity was
observed upon nPLA treatment (Figure 3a &3b). Further-
more, significant reduction in FITC-Annexin V stained
cells were observed in the astrocytoma exposed to STS and
treated with 0.01 μM nPLA. Hoechst33342 staining
showed that lesser number of DNA fragmentation occurs
in the presence of nPLA. Thus indicating that nPLA could
be mediating cell protection by reducing the apoptotic cell
death.
Hippocampal slice cultures subjected to OGD also
showed that 0.037 μM nPLA promoted about 60% and
95% survival at the CA1 and CA3 regions respectively,
whereas 0.075 μM nPLA showed 95% protection for both
regions. The protection mediated by nPLA (0.075 μM)
was similar to that observed for MK801, a selective non-
competitive antagonist of NMDA receptor. MK801 was
used as a positive control for neuroprotection as it has
been shown to be highly neuroprotective in both models
of ischemia and hypoxia [37,38]. We have also observed
that the protection shown in the presence of nPLA is
solely mediated by nPLA and not by intracellular PLA2
(iPLA2, cPLA2 or sPLA2). This is also because (a) similar
protection could not be observed in the vehicle treated
control slices subjected to OGD and (b) the endogenous
PLA2s are known to mediate cell death rather than protec-
tion in organotypic hippocampal slice cultures subjected
to OGD [11,13,14].
Gilroy et al [39] have also demonstrated that iPLA2 is
highly expressed at the onset phase of an acute inflamma-
tion with comparatively lower levels of sPLA2 (Groups 2A
and 5) as well as cPLA2 (Group 4) while the sPLA2 and
cPLA2 were the predominant isoforms expressed during
lesion resolution. Inhibition of both the cPLA and iPLA
has been proposed to be beneficial in reducing infarct vol-
ume and increasing the neurological activities of mice
subjected to MCAo [10,12] as well as increasing survival
and neuroprotection in in vitro experiments [11,13]. The
global gene expression data show that nPLA administra-
tion during MCAo reduces the iPLA2 but increases the
cPLA2 and sPLA2 expression (1B, 2A, 2B). In contrast to
the general observation that endogenous PLA2 promotes
pathophysiological condition, Forlenza et al [40] reported
that reduced endogenous PLA2 (cPLA and iPLA) activity
could impair neuronal viability and the functional integ-
rity of both calcium-dependent and calcium-independent
cytosolic PLA2. Endogenous sPLA2-X and human sPLA2-III
have been reported to promote neurite outgrowth in
PC12 cells [41,42], an effect that is not observed with the
administration of sPLA-1B or sPLA-IIA. It is noteworthy
that the nPLA belongs to the group 1A (sPLA-IA) which is
similar to the sPLA-1B but without the signature pancre-
atic loop.
We have also shown that nPLA could protect cell death
induced by glutamate (see Additional file 8) in the hip-
pocampal slice culture as well as in the astrocytoma cell
culture (CRL-1718™; Figure 2d-f). Furthermore, in a sepa-
rate in vitro study on astrocytes and hippocampii using
glutamate receptor agonists and antagonists as well as an
inhibitor to phospholipase activity (4-bromophenacyl
bromide), we have found that the nPLA mediated neuro-
protection is exerted via the mGluR, specifically mGluR1
and not by its phospholipase activity (unpublished data).BMC Neuroscience 2009, 10:120 http://www.biomedcentral.com/1471-2202/10/120
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Quantitative gene expression analysis on the MCAo
(+nPLA) ipsilateral brain (Figure 2c) and hippocampal
tissues subjected to OGD (+nPLA) (Figure 4c) showed
that the pro-survival (NFκB) and anti-apoptotic (Bcl-2
and Bcl-XL) genes were up-regulated while the pro-apop-
totic Bax gene was down-regulated upon nPLA adminis-
tration in both the in vivo and  in vitro studies. Bax
homodimer has been reported to activate apoptosis while
the heterodimer (with Bcl-2 or Bcl-XL) is known to inhibit
the process [43]. Elevated intracellular ratio of Bax to Bcl-
2 occurs during increased apoptotic cell death [44]. Simi-
larly, over-expression of Bcl-2 in in vivo ischemic studies
resulted in reduced apoptotic cell death [45,46]. Hence,
the quantitative real-time PCR results on the brain sample
subjected to MCAo and hippocampal slice culture sub-
jected to OGD, further support that apoptotic cell death is
reduced upon treatment with nPLA. The high expression
of both anti-apoptotic genes (Bcl-2 and Bcl-XL), could pos-
sibly result in Bax/Bcl-2 or Bcl-XL  heterodimerization,
thereby inhibiting apoptosis and promoting neuroprotec-
tion. Similarly, Neuroprotectin D1, derivative of docosa-
hexaenoic acid (DHA), that promotes strong
neuroprotection and neurotrophic activity following
ischemia and reperfusion, also up-regulates Bcl-2 and Bcl-
xL. Neuroprotectin D1 was also observed to inhibit the
caspase-3 activation [47]. However, nPLA improved cell
viability and survival in astrocytoma cells subjected to
OGD. The increase in cell viability was accompanied by
significant reduction in caspase-3 activity.
Consistently, reduction in caspase activity and increased
in cell viability have also been observed in staurosporine-
mediated apoptosis in astrocytoma cells treated with
nPLA (Figure 3a&3b). Oligonucleotide/DNA microarray
analysis also suggests that nPLA treatment in MCAo rats
reduce the impact of MCAo-mediated cellular damage to
normal (sham) level via inhibiting or reducing the effect
of apoptosis and inflammatory mechanisms, thus sup-
porting an anti-apoptotic regulation as a possible mecha-
nism of action for nPLA-mediated neuroprotection,
which is also consistent with our TUNNEL assays and
Real-time PCR analysis.
Regulation of water and ion channel genes
Apoptotic volume decrease (AVD), the earliest morpho-
logical event of apoptosis that is depicted by pronounced
cell shrinkage is believed to involve regulation of water
and ion channels. During AVD, intracellular ion concen-
trations are altered following inhibition of Na+/K+ATPase
in conjunction with a transient Na+ accumulation fol-
lowed by the extrusion of both Na+ and K+ ions from the
cell. Decreased intracellular K+ is in turn required for the
activation of the apoptotic/caspase cascade and optimal
nuclease activity [48]. Water movement during the AVD is
mediated primarily via aquaporins and that plasma mem-
brane water permeability directly affects the rate of apop-
totic progression [49]. Aquaporins have been shown to
play a pivotal role in the formation and clearance of fluid
(brain edema) during cerebral ischemia. The Aqp4 is a
water specific mercury insensitive water channel that is
found abundantly in brain and the Aqp9 is an aquaglycer-
oporin that conducts urea, lactate, arsenite, purine and
pyrimidines, besides water molecule [50]. Aquaporin 4
and 9 have been shown to be down-regulated in experi-
mental ischemic rat brain, while the Aqp4 knockout mice
subjected to MCAo showed smaller infarct volume. The
regression of ischemic infract also required an up-regula-
tion of Aqps [51]. Interestingly, in our study, both these
aquaporins (Aqp4 and 9) were up-regulated upon nPLA
administration. Up-regulation of Aqp9 therefore suggests
that the lactate and other solutes that were formed during
the ischemic injury may be channelled out of the cell via
Aqp9, thus could prove beneficial in neuroprotection.
Notably, the Kir4.1 and Na+/K+ATPase genes were also
upregulated upon nPLA administration in the MCAo rat.
Similarly, we have also observed that expression of the
aquaporin genes as well as the Kir4.1 and Na+/K+ATPase in
astrocytoma cells subjected to OGD (2 hr) were reversed
in the presence of nPLA. Expression of genes involved in
cell survival promoting pathway (PI3K, ERK1 and NFkB)
have also been significantly upregulated with nPLA
administration, indicating that an anti-apoptotic, homeo-
static (ionic/physiologic) and cell survival regulation are
being triggered in nPLA-mediated neuroprotection.
Conclusion
Snake venom PLA2 is known for its pathopharmacological
activities. We have shown here that nPLA, a potent toxin
isolated from Naja sputatrix venom, could reduce neuro-
nal cell death and promote cell survival both under in
vivo and in vitro ischemic conditions. Its beneficial effects
could be seen at a sublethal in vivo dose of 0.15 μg/g rats
(0.25 LD50) and at a concentration of 0.15 μM under in
vitro conditions.
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